• In vitro data indicate that the metabolism of hydroxyprogesterone caproate is predominantly mediated by CYP3A4 and CYP3A5. (nih.gov)
  • The in vitro data indicate that the caproate group is retained during metabolism of hydroxyprogesterone caproate. (drugcentral.org)
  • Hydroxyprogesterone Caproate Injection, USP is a sterile, long-acting preparation of the caproate ester of the naturally-occurring progestational hormone, hydroxyprogesterone, in an oil solution for intramuscular use. (nih.gov)
  • In advanced adenocarcinoma of the uterine corpus, Hydroxyprogesterone Caproate Injection in a dosage of 1,000 mg or more, one or more times each week, often induces regressive changes. (nih.gov)
  • Peak serum levels of hydroxyprogesterone caproate appeared after 3 to 7 days in non-pregnant female subjects following a single intramuscular injection of 1,000 mg hydroxyprogesterone caproate. (nih.gov)
  • Injection site reactions such as pain and swelling are the most common side effect of hydroxyprogesterone caproate. (wikipedia.org)
  • No specific pharmacodynamic studies were conducted with hydroxyprogesterone caproate injection. (drugcentral.org)
  • In single-dose, open-label, randomized, parallel design bioavailability study in 120 healthy post-menopausal women, comparable systemic exposure of hydroxyprogesterone caproate was seen when hydroxyprogesterone caproate injection was dosed intramuscularly (1 mL) in the upper outer quadrant of the gluteus maximus.Distribution: Hydroxyprogesterone caproate binds extensively to plasma proteins including albumin and corticosteroid binding globulins. (drugcentral.org)
  • Certain pregnancy-related fetal and maternal complications or events were numerically increased in the hydroxyprogesterone caproate injection-treated subjects as compared to control subjects, including miscarriage and stillbirth, admission for preterm labor, preeclampsia or gestational hypertension, gestational diabetes, and oligohydramnios (Tables and 2). (drugcentral.org)
  • 3 Progesterone is commercially available as an intramuscular injection, intravaginal gel, intravaginal insert, oral capsules, or powder for use in impromptu formulations (e.g., vaginal suppositories). (premierhormonehealth.com)
  • It is available for intramuscular injection in multiple dose vials containing 10,000 USP units of sterile dried 2017-05-30 2007-02-22 2007-05-16 FASS.se - läkemedelsinformation för vårdpersonal, patienter och veterinärer. (netlify.app)
  • Hydroxyprogesterone caproate is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. (wikipedia.org)
  • Therefore, our aim was to compare the administration of two different doses of vaginal progesterone with two doses of intramuscular (IM) progesterone for luteal phase support in patients undergoing IUI cycles. (jri.ir)
  • Hydroxyprogesterone caproate, sold under the brand names Proluton and Makena among others, is a medication used to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. (wikipedia.org)
  • Hydroxyprogesterone caproate is a progestin medication which was used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders. (wikipedia.org)
  • However, hydroxyprogesterone caproate was subsequently reintroduced in the United States under the brand name Makena for the treatment of preterm birth in 2011. (wikipedia.org)
  • The use of hydroxyprogesterone caproate in pregnancy to prevent preterm birth in women with a history of preterm delivery between 20 weeks and 36 weeks and 6 days is supported by the Society of Maternal Fetal Medicine Clinic Guidelines put out in May 2012 as Level I and III evidence, Level A recommendation. (wikipedia.org)
  • Absorption: Female patients with singleton pregnancy received intramuscular doses of 250 mg hydroxyprogesterone caproate for the reduction of preterm birth starting between 16 weeks days and 20 weeks days. (drugcentral.org)
  • Hydroxyprogesterone caproate is extensively metabolized and hepatic impairment may reduce the elimination of hydroxyprogesterone caproate. (nih.gov)
  • Each 5 mL multiple-dose vial contains hydroxyprogesterone caproate, 250 mg/mL, in castor oil (28.6% v/v) and benzyl benzoate (46% v/v) with the preservative benzyl alcohol (2% v/v). (nih.gov)
  • Three clinical studies in singleton pregnancies of 250 mg/week of intramuscular hydroxyprogesterone caproate have all shown a trend for an increase in pregnancy loss due to miscarriage compared to placebo. (wikipedia.org)
  • Following intramuscular administration to pregnant women at 10 to 12 weeks gestation, approximately 50% of dose was recovered in the feces and approximately 30% recovered in the urine. (drugcentral.org)
  • The pharmacokinetics of the 250 mg dose of hydroxyprogesterone caproate has not been evaluated in a study. (nih.gov)
  • A toxicology study in rhesus monkeys resulted in the death of all rhesus fetuses exposed to 1 and 10 times the human dose equivalent of hydroxyprogesterone caproate. (wikipedia.org)
  • the committee voted unanimously that further study was needed to evaluate the potential association of hydroxyprogesterone caproate with increased risk of second trimester miscarriage and stillbirth. (wikipedia.org)
  • Vaginal versus intramuscular progestogen for prevention of recurrent s" by Tanya L. Glenn, Rose A. Maxwell et al. (wright.edu)
  • OBJECTIVE: To evaluate whether vaginal progestogen (VP) can be substituted for intramuscular (IM) progestogen for the prevention of recurrent spontaneous pre-term delivery in a residency based high-risk obstetric clinic. (wright.edu)
  • Hydroxyprogesterone caproate is also contraindicated as a diagnostic test for pregnancy and in patients with current or history of thrombotic or thromboembolic disorders. (nih.gov)
  • There is no evidence of fetal risk with use of hydroxyprogesterone caproate during pregnancy. (wikipedia.org)
  • The effect of hepatic impairment on the pharmacokinetics of hydroxyprogesterone caproate has not been evaluated. (nih.gov)
  • The effect of renal impairment on the pharmacokinetics of hydroxyprogesterone caproate has not been evaluated. (nih.gov)
  • The elimination half-life of hydroxyprogesterone caproate, as evaluated from patients in the study who reached full-term in their pregnancies, was 16.4 (+3.6) days. (drugcentral.org)
  • Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. (medscape.com)
  • Hydroxyprogesterone caproate is contraindicated in women with a history of hypersensitivity to a progestin. (nih.gov)
  • One of them, a large National Institutes of Health (NIH) study in 2003, looked at the effect of hydroxyprogesterone caproate injections in women at risk for repeat premature birth and found that the treated group experienced premature birth in 37% versus 55% in the controls. (wikipedia.org)
  • Based on these NIH data, hydroxyprogesterone caproate was approved by the US Food and Drug Administration (FDA) in 2011, as a medication to reduce the risk of premature birth in selected women at risk. (wikipedia.org)
  • Overall, the findings indicate that hydroxyprogesterone caproate has minimal potential for CYP1A2, CYP2A6, and CYP2B6 related drug-drug interactions at the clinically relevant concentrations.In vitro data indicated that therapeutic concentration of hydroxyprogesterone caproate is not likely to inhibit the activity of CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. (drugcentral.org)
  • A follow-up study of the offspring showed no evidence that hydroxyprogesterone caproate affected the children in the first years of life. (wikipedia.org)
  • Drug InteractionsCytochrome P450 (CYP) enzymes: An in vitro inhibition study using human liver microsomes and CYP isoform-selective substrates indicated that hydroxyprogesterone caproate increased the metabolic rate of CYP1A2, CYP2A6, and CYP2B6 by approximately 80%, 150%, and 80%, respectively. (drugcentral.org)
  • However, in another in vitro study using human hepatocytes under conditions where the prototypical inducers or inhibitors caused the anticipated increases or decreases in CYP enzyme activities, hydroxyprogesterone caproate did not induce or inhibit CYP1A2, CYP2A6, or CYP2B6 activity. (drugcentral.org)
  • Metabolism:In vitro studies have shown that hydroxyprogesterone caproate can be metabolized by human hepatocytes, both by phase and phase II reactions. (drugcentral.org)
  • HALOPERIDOL LACTATE is a Psychiatric drug manufactured by Hikma and administered via the Intramuscular route of administration. (buyandbill.com)
  • Hydroxyprogesterone caproate 250 mg IM weekly preferably starting at 16-20 weeks until 36 weeks is recommended. (wikipedia.org)
  • In singleton gestations, 17 alpha-hydroxyprogesterone caproate (17P) has been shown to reduce the rate of recurrent preterm birth. (nih.gov)
  • Intramuscular 17-alpha hydroxyprogesterone caproate and oral dydrogesterone were both associated with significant reduction in miscarriage risk. (medscape.com)
  • Outrageous Price Charged for 17 alpha-hydroxyprogesterone caproate (17OHP): A Blessing in Disguise? (lamaze.org)
  • To assess whether 17 alpha-hydroxyprogesterone caproate reduces the rate of preterm birth in women carrying triplets. (elsevierpure.com)
  • The proportion of women experiencing the primary outcome (a composite of delivery or fetal loss before 35 0/7 weeks) was similar in the two treatment groups: 83% of pregnancies in the 17 alpha-hydroxyprogesterone caproate group and 84% in the placebo group, relative risk 1.0, 95% confidence interval 0.9-1.1. (elsevierpure.com)
  • The lack of benefit of 17 alpha-hydroxyprogesterone caproate was evident regardless of the conception method or whether a gestational age cutoff for delivery was set at 32 or 28 weeks. (elsevierpure.com)
  • Treatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with triplet gestations. (elsevierpure.com)
  • Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. (bio-japan.net)
  • One of them, a large National Institutes of Health (NIH) study in 2003, looked at the effect of hydroxyprogesterone caproate injections in women at risk for repeat premature birth and found that the treated group experienced premature birth in 37% versus 55% in the controls. (wikipedia.org)
  • Healthy women with twin gestations were assigned to weekly intramuscular injections of 250 mg of 17P or matching placebo, starting at 16 to 20 weeks of gestation and ending at 35 weeks. (nih.gov)
  • Dosage and administration of Japanese Progeston Depot injections 125 mg for gynecological disorders In most of cases please take as intramuscular injection, 65-125 mg of active ingredient (0.5 or 1 ampoule) 1 time a week. (bio-japan.net)
  • Weekly intramuscular injections of 17- alpha hydroxyprogesterone beginning between 16-21 weeks gestation has been associated with a 33% reduction in the rate of recurring preterm delivery. (mombaby.org)
  • This study was performed to compare oral Dydrogesterone with intramuscular 17α-hydroxyprogesterone caproate (17α-OHPC) administration in prevention of PTB. (nih.gov)
  • The use of hydroxyprogesterone caproate in pregnancy to prevent preterm birth in women with a history of preterm delivery between 20 weeks and 36 weeks and 6 days is supported by the Society of Maternal Fetal Medicine Clinic Guidelines put out in May 2012 as Level I and III evidence, Level A recommendation. (wikipedia.org)
  • 17 hydroxyprogesterone for the prevention of preterm delivery. (mombaby.org)
  • Hydroxyprogesterone caproate is a progestin medication which was used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders. (wikipedia.org)
  • The active pharmaceutical ingredient in Makena is hydroxyprogesterone caproate, a progestin. (mdtodate.com)
  • Hydroxyprogesterone caproate is a synthetic progestin. (mdtodate.com)
  • Injection site reactions such as pain and swelling are the most common side effect of hydroxyprogesterone caproate. (wikipedia.org)
  • Many women are uncertain about what treatments are safe to use during their pregnancy, and one such treatment is hydroxyprogesterone injection. (mylofamily.com)
  • It's important for women to understand what hydroxyprogesterone injection is, the benefits and risks of using it during pregnancy, how it is administered, and possible alternatives. (mylofamily.com)
  • What is Hydroxyprogesterone Injection? (mylofamily.com)
  • It is most commonly given in the form of an intramuscular injection, and is typically given between weeks 16 and 20 of pregnancy. (mylofamily.com)
  • Hydroxyprogesterone injection is typically given as an intramuscular injection. (mylofamily.com)
  • It is important to note that hydroxyprogesterone injection should only be given by a healthcare provider who is experienced in administering the injection. (mylofamily.com)
  • Hydroxyprogesterone injection during pregnancy has been shown to reduce the risk of preterm labor and preterm birth in women who are at higher risk for such complications. (mylofamily.com)
  • Finally, hydroxyprogesterone injection has been shown to improve the outcomes of pregnancies for women with a history of preterm labor or birth. (mylofamily.com)
  • Studies have found that the use of hydroxyprogesterone injection is associated with a decreased risk of delivering a baby that is too small for gestational age, as well as a decreased risk of neonatal death. (mylofamily.com)
  • While hydroxyprogesterone injection is generally considered safe and effective, there are some potential risks associated with its use during pregnancy. (mylofamily.com)
  • In rare cases, hydroxyprogesterone injection may cause more serious side effects, such as depression, anxiety, and vision problems. (mylofamily.com)
  • It is also important to note that hydroxyprogesterone injection is not recommended for women who have a history of depression or anxiety, as it may worsen these conditions. (mylofamily.com)
  • Additionally, it is important to talk to your healthcare provider about any other medications you are taking, as some medications may interact negatively with hydroxyprogesterone injection. (mylofamily.com)
  • In addition to the potential side effects described above, there are also some potential complications associated with the use of hydroxyprogesterone injection during pregnancy. (mylofamily.com)
  • Makena is a clear, yellow, sterile, non-pyrogenic solution for intramuscular (vials) or subcutaneous (auto-injector) injection. (mdtodate.com)
  • in the upper outer area of the buttocks as an injection into the muscle (intramuscular). (mdtodate.com)
  • Hydroxyprogesterone caproate 250 mg IM weekly preferably starting at 16-20 weeks until 36 weeks is recommended. (wikipedia.org)
  • Hydroxyprogesterone caproate, sold under the brand names Proluton and Makena among others, is a medication used to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. (wikipedia.org)
  • However, hydroxyprogesterone caproate was subsequently reintroduced in the United States under the brand name Makena for the treatment of preterm birth in 2011. (wikipedia.org)
  • a history of allergic reaction to hydroxyprogesterone caproate, castor oil, or any of the other ingredients in Makena. (mdtodate.com)
  • Subgroup analysis revealed that oral, intramuscular, and synthetic progestogens were associated with lower risk for miscarriage . (medscape.com)
  • the committee voted unanimously that further study was needed to evaluate the potential association of hydroxyprogesterone caproate with increased risk of second trimester miscarriage and stillbirth. (wikipedia.org)
  • Based on these NIH data, hydroxyprogesterone caproate was approved by the US Food and Drug Administration (FDA) in 2011, as a medication to reduce the risk of premature birth in selected women at risk. (wikipedia.org)
  • Studies to date have demonstrated that hydroxyprogesterone is not associated with congenital anomalies or other neonatal developmental problems. (mombaby.org)
  • Analysis of MPA in plasma or serum has been performed to study its pharmacokinetics and to monitor its residual levels in cancer patients after oral or intramuscular administration [ 4 , 5 ]. (intechopen.com)
  • abametapir will increase the level or effect of hydroxyprogesterone caproate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
  • apalutamide will decrease the level or effect of hydroxyprogesterone caproate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
  • clarithromycin will increase the level or effect of hydroxyprogesterone caproate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
  • enzalutamide will decrease the level or effect of hydroxyprogesterone caproate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
  • erythromycin base will increase the level or effect of hydroxyprogesterone caproate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. (medscape.com)
  • Depot-MPA is widely used by intramuscular administration for long-term contraception [ 1 - 3 ]. (intechopen.com)
  • Hydroxyprogesterone caproate was discovered in 1953 and was introduced for medical use in 1954 or 1955. (wikipedia.org)
  • The chemical name for hydroxyprogesterone caproate is pregn-4-ene-3,20-dione, 17[(1-oxohexyl)oxy]. (mdtodate.com)
  • Their derivatives are orally active medroxyprogesterone acetate including hydroxyprogesterone caproate, chlormadinone acetate, megestrol acetate. (intechopen.com)
  • Hydroxyprogesterone caproate is generally well tolerated and produces few side effects. (wikipedia.org)
  • A follow-up study of the offspring showed no evidence that hydroxyprogesterone caproate affected the children in the first years of life. (wikipedia.org)
  • A toxicology study in rhesus monkeys resulted in the death of all rhesus fetuses exposed to 1 and 10 times the human dose equivalent of hydroxyprogesterone caproate. (wikipedia.org)